Pharsight

Pomalyst is owned by Celgene.

Pomalyst contains Pomalidomide.

Pomalyst has a total of 12 drug patents out of which 0 drug patents have expired.

Pomalyst was authorised for market use on 08 February, 2013.

Pomalyst is available in capsule;oral dosage forms.

Pomalyst can be used as use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy; use of pomalidomide for the treatment of multiple myeloma, use of pomalidomide for the treatment of multiple myeloma; use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy.

The generics of Pomalyst are possible to be released after 21 December, 2031.

Application	Filing Date	Opposition Party	Legal Status
EP18160247A	2020-01-10	Hoffmann Eitle	Granted and Under Opposition
EP18160247A	2020-01-09	Generics (UK) Ltd	Granted and Under Opposition
EP18160247A	2020-01-08	HGF Limited	Granted and Under Opposition
EP18160247A	2019-12-16	Pruß, Timo	Granted and Under Opposition
EP15199521A	2019-08-07	Hamm&Wittkopp Patentanwälte PartmbB	Revoked
EP15199521A	2019-08-07	Bachelin, Martin, Dr.	Revoked
EP15199521A	2019-08-07	Generics [UK] Ltd	Revoked
EP15199540A	2019-08-07	Generics (UK) Ltd	Revoked
EP15199526A	2019-08-07	Generics [UK] Ltd	Revoked
EP15199521A	2019-07-25	Pruß, Timo	Revoked
EP15199521A	2019-07-25	Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB	Revoked
EP10720107A	2017-10-18	STADA Arzneimittel AG	Revoked
EP10720107A	2017-10-18	Hoffmann Eitle	Revoked
EP10720107A	2017-10-17	Generics [UK] Ltd	Revoked
EP10720107A	2017-10-17	HGF Limited	Revoked
EP10720107A	2017-10-12	Teva Pharmaceutical Industries Ltd	Revoked
EP09008756A	2015-07-22	Accord Healthcare Ltd	Revoked
EP09008756A	2015-07-21	Hexal AG	Revoked
EP09008756A	2015-07-21	Generics [UK] Limited (trading as Mylan)	Revoked
EP09008756A	2015-07-20	Intellectual Property Services	Revoked
EP09008756A	2015-07-17	Synthon B.V.	Revoked
EP09008756A	2015-07-14	Actavis Group PTC EHF	Revoked
EP04783095A	2012-08-02	Teva Pharmaceutical Industries Ltd.	Revoked
EP04783095A	2012-08-01	Generics [UK] Limited	Revoked
EP03728969A	2010-12-01	STRAWMAN LIMITED	Revoked
EP03728969A	2010-11-30	Synthon B.V.	Revoked

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8828427	CELGENE	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	Jun, 2031 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673939	CELGENE	Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione	May, 2023 (a month from now)
US8735428	CELGENE	Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione	May, 2023 (a month from now)
US8735428 (Pediatric)	CELGENE	Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione	Nov, 2023 (7 months from now)
US8673939 (Pediatric)	CELGENE	Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione	Nov, 2023 (7 months from now)
US8198262	CELGENE	Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione	Jun, 2025 (2 years from now)
US8198262 (Pediatric)	CELGENE	Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione	Dec, 2025 (2 years from now)
US9993467	CELGENE	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	May, 2030 (7 years from now)
US10555939	CELGENE	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	May, 2030 (7 years from now)
US9993467 (Pediatric)	CELGENE	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	Nov, 2030 (7 years from now)
US10555939 (Pediatric)	CELGENE	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	Nov, 2030 (7 years from now)
US8828427 (Pediatric)	CELGENE	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	Dec, 2031 (8 years from now)

Exclusivity	Exclusivity Expiration
M (M)	Nov 20, 2023
Orphan Drug Exclusivity (ODE)	May 14, 2027
Pediatric Exclusivity (PED)	May 20, 2024

Drugs and Companies using POMALIDOMIDE ingredient

Market Authorisation Date: 08 February, 2013

Treatment: Use of pomalidomide for the treatment of multiple myeloma; Use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy

Dosage: CAPSULE;ORAL